Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2009

SeqWright and Lilly to Sequence Genomic Regions Associated with Psychiatric Diseases Using Roche Technologies

  • Roche Applied Science will supply Eli Lilly and SeqWright with technologies to identify genetic variants associated with various psychiatric diseases. SeqWright will utilize NimbleGen sequence capture technology to selectively enrich approximately 40 megabases of the human genome. This will then be sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

    “Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost-effective manner,” remarks Brian Edmonds, Ph.D., research advisor, global external research and development, Eli Lilly.  “Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes. We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »